Haoran Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haoran Chang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Jisheng Wang
Andrology Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
3 shared publications - Xiangfa Lin
Beijing University of Chinese Medicine
3 shared publications Haisong Li
Beijing University of Chinese Medicine
2 shared publicationsHui Chen
Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital
2 shared publications- Junlong Feng
First Clinical Medical College, Beijing University of Chinese Medicine, Beijing, China
2 shared publications - Li-Xing Lei
Beijing University of Chinese Medicine
2 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by SAGE Publications in American Journal of Men's Health
- Vol. 20 (5)
A Combination of Cuscuta chinensis and Lycium barbarum Ameliorates Spermatogenic Impairment in Mice and Is Associated With Modulation of the miR-21/PTEN/PI3K/AKT/mTOR Signaling Axis
SC-FL is a traditional Chinese herbal formula that has been used for kidney tonification and the clinical treatment of oligospermia and asthenospermia. This medicinal compound comprises dodder seed ( Cuscuta chinensis Lam .) and wolfberry fruit ( Lycium barbarum L .). However, the precise mechanisms of SC-FL remain undetermined. Therefore, this study aimed to identify potential therapeutic targets of SC-FL in oligoasthenozoospermia and validate these targets in vivo . To establish a spermatogenic dysfunction model, male BALB/c mice were administered glucosides of Tripterygium wilfordii Hook. f. (GTW) and then treated with SC-FL. Furthermore, the expression of microRNA-21 (miR-21), key PI3K/AKT/mTOR signaling pathway-related proteins and mRNAs, as well as molecular markers of cell proliferation and apoptosis, was evaluated. The results indicated that the mouse body weight did not significantly differ across SC-FL-treated groups compared to the GTW group (non-treated model group); however, the high-dose SC-FL mice showed significantly higher testicular weight ( p < 0.05 ). Both medium- and high-dose SC-FL mice showed significantly increased sperm concentration and motility relative to the GTW group ( p < 0.01 ). Histological analysis by hematoxylin and eosin staining revealed that SC-FL treatment alleviated GTW-induced testicular tissue damage and preserved testicular structure. SC-FL treatment reduced serum IL-6 and TNF-α levels and decreased PTEN mRNA and protein expression. It also increased miR-21, PI3K, AKT, and mTOR mRNA expression and increased the phosphorylated protein levels of PI3K, AKT, and mTOR, whereas total PI3K, AKT, and mTOR protein abundance remained relatively unchanged. In conclusion, SC-FL increased sperm concentration and motility and reduced serum inflammatory cytokine levels in mice. These beneficial effects were accompanied by increased miR-21 expression, decreased PTEN expression, and increased phosphorylation of PI3K, AKT, and mTOR. These findings indicate an association between the protective effects of SC-FL and alterations in the miR-21/PTEN/PI3K/AKT/mTOR signaling axis, but do not establish causal mediation by this pathway.
- 28 September 2026
- Published by SAGE Publications in American Journal of Men's Health
- Vol. 20 (5)
Open AccessA Combination of Cuscuta chinensis and Lycium barbarum Ameliorates Spermatogenic Impairment in Mice and Is Associated With Modulation of the miR-21/PTEN/PI3K/AKT/mTOR Signaling Axis
SC-FL is a traditional Chinese herbal formula that has been used for kidney tonification and the clinical treatment of oligospermia and asthenospermia. This medicinal compound comprises dodder seed ( Cuscuta chinensis Lam .) and wolfberry fruit ( Lycium barbarum L .). However, the precise mechanisms of SC-FL remain undetermined. Therefore, this study aimed to identify potential therapeutic targets of SC-FL in oligoasthenozoospermia and validate these targets in vivo . To establish a spermatogenic dysfunction model, male BALB/c mice were administered glucosides of Tripterygium wilfordii Hook. f. (GTW) and then treated with SC-FL. Furthermore, the expression of microRNA-21 (miR-21), key PI3K/AKT/mTOR signaling pathway-related proteins and mRNAs, as well as molecular markers of cell proliferation and apoptosis, was evaluated. The results indicated that the mouse body weight did not significantly differ across SC-FL-treated groups compared to the GTW group (non-treated model group); however, the high-dose SC-FL mice showed significantly higher testicular weight ( p < 0.05 ). Both medium- and high-dose SC-FL mice showed significantly increased sperm concentration and motility relative to the GTW group ( p < 0.01 ). Histological analysis by hematoxylin and eosin staining revealed that SC-FL treatment alleviated GTW-induced testicular tissue damage and preserved testicular structure. SC-FL treatment reduced serum IL-6 and TNF-α levels and decreased PTEN mRNA and protein expression. It also increased miR-21, PI3K, AKT, and mTOR mRNA expression and increased the phosphorylated protein levels of PI3K, AKT, and mTOR, whereas total PI3K, AKT, and mTOR protein abundance remained relatively unchanged. In conclusion, SC-FL increased sperm concentration and motility and reduced serum inflammatory cytokine levels in mice. These beneficial effects were accompanied by increased miR-21 expression, decreased PTEN expression, and increased phosphorylation of PI3K, AKT, and mTOR. These findings indicate an association between the protective effects of SC-FL and alterations in the miR-21/PTEN/PI3K/AKT/mTOR signaling axis, but do not establish causal mediation by this pathway.
- Open Access
- 4 September 2026
- Published by SAGE Publications in American Journal of Men's Health
- Vol. 20 (5)
CP1Hao Decoction Alleviates Chronic Prostatitis by Modulating Arachidonic Acid Metabolism: A Multi-Omics Analysis
CP1Hao Decoction (CP1HD) is a traditional Chinese herbal prescription used to treat chronic prostatitis, but the therapeutic effects and underlying mechanisms of CP1HD, particularly those involving arachidonic acid metabolism and gut microbiota, remain unclear. This study evaluated the pharmacological efficacy of CP1HD in a carrageenan-induced rat model of prostatitis and explored its potential targets and pathways through integrated transcriptomics, 16S rRNA sequencing, and metabolomics analyses. CP1HD treatment significantly alleviated prostate histopathological damage, reduced the prostate index, and suppressed inflammatory responses. ELISA results showed that CP1HD markedly decreased the levels of TNF-α, IL-6, PGE2, LTB4, and COX-2, while regulating EETs levels, and inhibited M1 macrophage polarization and neutrophil infiltration while promoting M2 polarization. Transcriptomic analysis revealed that CP1HD reversed differentially expressed genes associated with inflammation and arachidonic acid metabolism, which was further confirmed by Western blot analysis of cPLA2, LTA4H, and sEH. In addition, CP1HD modulated gut microbiota composition by restoring the relative abundance of Bacteroides , Alistipes , and the Eubacterium_siraeum group . Metabolomic profiling demonstrated that CP1HD regulated arachidonic acid metabolism and related lipid mediators, with notable effects on phosphatidylethanolamine metabolism and fatty acid β-oxidation. Overall, CP1HD ameliorates prostatitis by reducing inflammation and prostate injury while modulating arachidonic acid metabolism, gut microbiota, and associated metabolic pathways.
- 4 September 2026
- Published by SAGE Publications in American Journal of Men's Health
- Vol. 20 (5)
Open AccessCP1Hao Decoction Alleviates Chronic Prostatitis by Modulating Arachidonic Acid Metabolism: A Multi-Omics Analysis
CP1Hao Decoction (CP1HD) is a traditional Chinese herbal prescription used to treat chronic prostatitis, but the therapeutic effects and underlying mechanisms of CP1HD, particularly those involving arachidonic acid metabolism and gut microbiota, remain unclear. This study evaluated the pharmacological efficacy of CP1HD in a carrageenan-induced rat model of prostatitis and explored its potential targets and pathways through integrated transcriptomics, 16S rRNA sequencing, and metabolomics analyses. CP1HD treatment significantly alleviated prostate histopathological damage, reduced the prostate index, and suppressed inflammatory responses. ELISA results showed that CP1HD markedly decreased the levels of TNF-α, IL-6, PGE2, LTB4, and COX-2, while regulating EETs levels, and inhibited M1 macrophage polarization and neutrophil infiltration while promoting M2 polarization. Transcriptomic analysis revealed that CP1HD reversed differentially expressed genes associated with inflammation and arachidonic acid metabolism, which was further confirmed by Western blot analysis of cPLA2, LTA4H, and sEH. In addition, CP1HD modulated gut microbiota composition by restoring the relative abundance of Bacteroides , Alistipes , and the Eubacterium_siraeum group . Metabolomic profiling demonstrated that CP1HD regulated arachidonic acid metabolism and related lipid mediators, with notable effects on phosphatidylethanolamine metabolism and fatty acid β-oxidation. Overall, CP1HD ameliorates prostatitis by reducing inflammation and prostate injury while modulating arachidonic acid metabolism, gut microbiota, and associated metabolic pathways.
- Open Access
- 10 March 2026
- Published by SAGE Publications in American Journal of Men's Health
- Vol. 20 (2)
The Guangsi Yulin Decoction Inhibits Oxidative Stress and Inflammation-Induced Spermatogenesis Dysfunction via the PTEN / PI3K / AKT / FoxO1 Pathway
Guangsi Yulin Decoction (GSYLD) is a traditional Chinese medicine (TCM) formula with therapeutic efficacy against spermatogenesis dysfunction. However, the underlying mechanism of the alleviation remains unclear. To investigate the effects of GSYLD on Tripterygium wilfordii polyglycolide (GTW)-induced spermatogenesis dysfunction in mice and to explore associated mechanisms, particularly its role in oxidative stress and inflammation. A total of 60 (7–8-week-old) BALB/c mice were grouped into control (NC), model (GTW), low-dose GSYLD (GSYLD-L, 0.27 g/kg/d), high-dose GSYLD (GSYLD-H, 1.08 g/kg/d), and PTEN inhibitor (1.08 g/kg/d GSYLD-H + 0.3 mg/kg PTEN inhibitor). After eight weeks, the model was validated, and semen quality was evaluated by assessing sperm vitality and concentration. Testicular tissues were analyzed by H&E staining, while Western blotting and RT-qPCR (Reverse Transcription Quantitative PCR) were used to assess the therapeutic efficacy of the GSYLD. In comparison to the GTW group, the GSYLD-H group showed a significant improvement in sperm vitality and concentration ( p < .01). GSYLD upregulated PI3K , AKT , and FoxO1 , while downregulating PTEN mRNA expression ( p < .001). A parallel recovery was observed at the protein level. Specifically, the GSYLD-H group exhibited a significant amelioration of oxidative stress and inflammation, marked by reduced MDA, TNF-α, and IL-6 levels ( p < .01) and enhanced SOD activity ( p < .001) relative to the GTW group. GSYLD alleviated GTW-induced spermatogenesis dysfunction, potentially through PTEN / PI3K / AKT / FoxO1 -mediated regulation of oxidative stress and inflammation.
- 10 March 2026
- Published by SAGE Publications in American Journal of Men's Health
- Vol. 20 (2)
Open AccessThe Guangsi Yulin Decoction Inhibits Oxidative Stress and Inflammation-Induced Spermatogenesis Dysfunction via the PTEN / PI3K / AKT / FoxO1 Pathway
Guangsi Yulin Decoction (GSYLD) is a traditional Chinese medicine (TCM) formula with therapeutic efficacy against spermatogenesis dysfunction. However, the underlying mechanism of the alleviation remains unclear. To investigate the effects of GSYLD on Tripterygium wilfordii polyglycolide (GTW)-induced spermatogenesis dysfunction in mice and to explore associated mechanisms, particularly its role in oxidative stress and inflammation. A total of 60 (7–8-week-old) BALB/c mice were grouped into control (NC), model (GTW), low-dose GSYLD (GSYLD-L, 0.27 g/kg/d), high-dose GSYLD (GSYLD-H, 1.08 g/kg/d), and PTEN inhibitor (1.08 g/kg/d GSYLD-H + 0.3 mg/kg PTEN inhibitor). After eight weeks, the model was validated, and semen quality was evaluated by assessing sperm vitality and concentration. Testicular tissues were analyzed by H&E staining, while Western blotting and RT-qPCR (Reverse Transcription Quantitative PCR) were used to assess the therapeutic efficacy of the GSYLD. In comparison to the GTW group, the GSYLD-H group showed a significant improvement in sperm vitality and concentration ( p < .01). GSYLD upregulated PI3K , AKT , and FoxO1 , while downregulating PTEN mRNA expression ( p < .001). A parallel recovery was observed at the protein level. Specifically, the GSYLD-H group exhibited a significant amelioration of oxidative stress and inflammation, marked by reduced MDA, TNF-α, and IL-6 levels ( p < .01) and enhanced SOD activity ( p < .001) relative to the GTW group. GSYLD alleviated GTW-induced spermatogenesis dysfunction, potentially through PTEN / PI3K / AKT / FoxO1 -mediated regulation of oxidative stress and inflammation.